Therefore, YTN16 tumor-bearing mice were treated with ICI using anti-PD-1, anti-PD-L1 or anti-CTLA-4 mAbs, to test whether T cell-mediated immunity against YTN16 tumors could be generated. Here, CTLA4 is linked to neoplasm.